Objective To define headache characteristics and evolution in relation to COVID-19 and its
inflammatory response. Methods This is a prospective study, comparing clinical data and …

Background In daily practice, anti-CGRP monoclonal antibodies (MAbs) may be useful in
chronic migraine (CM) with medication overuse (MO), but data is limited. We evaluated their …

Chronic migraine is a neurological disorder characterized by 15 or more headache days per
month of which at least 8 days show typical migraine features. The process that describes …

Objective We aimed (1) to analyze salivary calcitonin gene‐related peptide (CGRP) levels in
patients with migraine, (2) to predict erenumab response from baseline CGRP levels, and (3…

Objective To evaluate the frequency and headache-related impact response to monoclonal
antibodies against calcitonin gene-related peptide (CGRP) in a clinical sample of refractory …

One year after the outbreak of coronavirus disease 2019 (COVID‐19), referrals for persistent
headache, often defined as “post‐COVID headache,” have become increasingly common in …

Background CGRP plays a key role in the transmission and modulation of nociceptive signals
and is a critical component in the pathogenesis of migraine. Objective To assess saliva as …

Background Erenumab was approved in Europe for migraine prevention in patients with ≥ 4
monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access …

Background Anti-CGRP monoclonal antibodies have shown notable effectiveness and
tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as …

Background There is a need to establish which are the more relevant headache-related
outcomes that have an impact on our patient’s lives to accurately evaluate treatment response in …